Document is current
Any future updates will be listed below
-
Authors
Sandmann, Abel Clemens Adriaan https://orcid.org/0009-0008-9744-8544
Kempeneers, Marinus Abraham https://orcid.org/0000-0003-2860-4458
Slot, K. Mariam https://orcid.org/0000-0002-5680-5620
van den Berg, René https://orcid.org/0000-0002-8791-8791
Vandertop, William Peter https://orcid.org/0000-0001-5417-0265
Verbaan, Dagmar https://orcid.org/0000-0002-9212-5470
Coutinho, Jonathan M. https://orcid.org/0000-0002-8284-982X
- License Information
-
More Information
Article History
Received: 27 November 2025
Revised: 5 February 2026
Accepted: 15 February 2026
First Online: 8 March 2026
Declarations
:
: Jonathan M. Coutinho received financial support from Bayer and AstraZeneca (all fees were paid to his employer), and is co-founder and shareholder of TrianecT. René van den Berg has a non-personal hospital consultancy at Johnson & Johnson (CERENOVUS). All other authors declare that there are no relevant financial or non-financial interests to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. The Institutional Review Board of the Amsterdam UMC waived the need for formal ethical approval due to the study’s observational design (W22_196 # 22.244). All participants first underwent an opt-out procedure for the reuse of clinical data and subsequently provided informed consent if the questionnaire was completed.
